Compare Ascendis Pharma A/S (ASND) vs Expedia Group Inc (EXPE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Expedia Group Inc — how do they compare? Ascendis Pharma A/S trades at $253.09 (market cap $16.67B), while Expedia Group Inc trades at $319.11 (market cap $38.53B). The key difference: Expedia Group Inc is far larger — about 2.3× Ascendis Pharma A/S's market cap, and Expedia Group Inc pays a 0.6% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | EXPE | |
|---|---|---|
Market Cap | $16.67B | $38.53B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $321.07 |
52-Week Low | $189.74 | $188.51 |
Enterprise Value | $17.04B | $37.09B |
Dividend Yield | — | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
Expedia Group (EXPE) trades at $314.01, up 1.07% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q2 2026 EPS of $5.76 beating estimates by 10.3% and revenue growth accelerating to 14% year-over-year. Recent earnings show continued B2B momentum and AI-driven efficiency improvements, with the company raising full-year revenue guidance to $16.05-16.22 billion. Valuation metrics remain reasonable with P/E of 20.19 and EV/EBITDA of 10.04, while profitability metrics show impressive ROE of 199.12% and net margin of 12.97%.
Expedia presents a favorable investment case with strong earnings momentum, strategic AI integration, and upward guidance revisions. The stock trades near analyst consensus target of $322.95 with 47% buy ratings, though RSI levels suggest potential near-term overbought conditions. Key risks include travel demand sensitivity to economic conditions and competitive pressures in online travel. The combination of fundamental strength and technical momentum supports a constructive outlook for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →
